Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
18.4M
-
Shares change
-
-15.8M
-
Total reported value, excl. options
-
$91.9M
-
Value change
-
-$79.6M
-
Put/Call ratio
-
0.73
-
Number of buys
-
15
-
Number of sells
-
-26
-
Price
-
$5.00
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q1 2018
56 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q1 2018.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.4M shares
of 193M outstanding shares and own 9.5% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (5.15M shares), PRIMECAP MANAGEMENT CO/CA/ (4M shares), LADENBURG THALMANN FINANCIAL SERVICES INC. (1.77M shares), Foresite Capital Management IV, LLC (1.49M shares), BANK OF MONTREAL /CAN/ (882K shares), D. E. Shaw & Co., Inc. (710K shares), BlackRock Inc. (690K shares), AXA (536K shares), MORGAN STANLEY (514K shares), and Hudson Bay Capital Management LP (360K shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.